Azedra: Phase IIb start

Progenics said it plans to resume an open-label, U.S., pivotal Phase IIb trial evaluating 2 doses of 500 mCi or 8 mCi/kg Azedra given about 3 months apart in about 75 patients. The company hopes to re...